cvl-354
Small moleculeexperimental
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 18, 2021 (NCT05138653)
Timeline
Indications
Mechanism of action
- Kappa opioid receptorANTAGONIST
OPRK1 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
COc1nn(C)cc1[C@@H]1CCCN1Cc1ccc(Oc2ccc(C(N)=O)cc2)cc1- Mol. weight
- 406.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314519 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07276997 | Phase 2 | Jan 8, 2026 | AbbVie |
| NCT07219017 | Phase 1 | Oct 15, 2025 | AbbVie |
| NCT06696755 | Phase 2 | May 15, 2025 | AbbVie |
| NCT06722417 | Phase 1 | Dec 2, 2024 | AbbVie |
| NCT06722430 | Phase 1 | Nov 13, 2024 | AbbVie |
| NCT05547542 | Phase 1 | Dec 30, 2022 | Cerevel Therapeutics, LLC |
| NCT05138653 | Phase 1 | Oct 18, 2021 | Cerevel Therapeutics, LLC |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 5 | 5 | 2 | 2024 |
| Cerevel Therapeutics, LLC | For profit | 2 | 2 | 1 | 2021 |
2 organizations
Page 1 / 1